Powered by: Motilal Oswal

News

Sell Dr Lal Pathlabs Ltd For Target Rs. . 2,110 - Geojit Financial Services Ltd Valuation stretched; downgraded the stock Dr. Lal PathLabs Ltd provides diagnostic and related healthcare tests and services globally. The company had 277 clinical laboratories, including a national reference lab in Delhi, a regional reference lab in Kolkata, 5,102 patient service centres, and 10,938 pick-up points as of March 2023. * In Q1FY24, revenue grew 7.6% YoY to Rs. 541cr, led by an increase in prices, a favourable test mix, and the growing contribution of Swasthfit, a full-body...
Sell Dr Lal Pathlabs Ltd For Target Rs. . 2,110 - Geojit Financial Services Ltd
Sell Dr Lal Pathlabs Ltd For Target Rs. . 2,110 - Geojit Financial Services Ltd
Source: Geojit Financial Services Ltd
12/08/2023 2:26:48 PM
Buy Dr Lal Pathlabs Ltd For Target Rs. 2,610 - JM Financial Institutional Securities DLPL reported high single digit revenue growth with very strong EBITDA margin of 27% (350bps beat vs. JMFe). Price hikes, lower consumption costs and better portfolio mix aided margins. Non-Covid revenues grew 9.7%YoY. While volumes were tad below expectations primarily due to deferred seasonality, we expect it to recover in 2Q. DLPL is also increasing ad-spends and started a new marketing campaign “Bharat ka Vishwas” to enhance growth. Swasthfit contribution continues to rise (22...
Buy Dr Lal Pathlabs Ltd For Target Rs. 2,610 - JM Financial Institutional Securities
Buy Dr Lal Pathlabs Ltd For Target Rs. 2,610 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities Ltd
5/08/2023 10:25:06 AM
Buy Dr Lal Pathlabs Ltd For Target Rs. 2,525 - JM Financial Institutional Securities DLPL reported 4Q numbers with mid-teens non-Covid growth (incl. Suburban) with better than expected adj. margins of c. 25%. Price hike in high-end tests in Feb’23 aided 1.7% incremental growth in revenue and is expected to continue in FY24. Swasthfit contribution continues to rise (22% in 4Q), generally higher in 4Q. Suburban margins remain subdued at 11.2% in 4Q due to Mumbai lab overheads. We expect double digit growth and margin expansion for DLPL over FY23-25 aided by price hikes, h...
Buy Dr Lal Pathlabs Ltd For Target Rs. 2,525 - JM Financial Institutional Securities
Buy Dr Lal Pathlabs Ltd For Target Rs. 2,525 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities
16/05/2023 2:30:34 PM
India's Dr. Lal PathLabs reports decline in Q4 profit India's Dr. Lal PathLabs Ltd on Thursday reported a sixth consecutive fall in quarterly profit as a continued slide in income from COVID-related testing outpaced growth in its core business. The medical diagnostics firm, India's largest by revenue, posted a consolidated net profit of 567 million rupees ($6.93 million) in the three months to March 31, down from 613 million rupees a year earlier. Earnings margin before interest, taxes, depreciation, and amortisation contracted to ...
India's Dr. Lal PathLabs reports decline in Q4 profit
India's Dr. Lal PathLabs reports decline in Q4 profit
Source: Reuters
11/05/2023 3:56:46 PM
Buy Fusion Micro Finance For Target Rs 570 -JM Financial Institutional Securities Ltd We recently hosted the management of Fusion Micro Finance for an NDR. Management reiterated its focus on deepening presence and driving customer growth without chasing ticket size led growth. Growth is likely to come from existing districts given Fusion is already is present in 20 states and currently no district is >3% of overall AUM for Fusion. The company aspires to maintain healthy medium growth trajectory (3QFY23 AUM grew 45% YoY) without losing sight of risk parameters. Fusion aspire...
Buy Fusion Micro Finance For Target Rs 570 -JM Financial Institutional Securities Ltd
Buy Fusion Micro Finance For Target Rs 570 -JM Financial Institutional Securities Ltd
Source: JM Financial Institutional Securities Ltd
23/03/2023 12:05:16 PM
Buy Gail India Ltd For Target Rs .125- JM Financial Institutional Securities Ltd We attended GAIL’s analyst meet today. During the interaction, the management highlighted that the revised integrated tariff of INR 58.61/mmbtu is a positive for the company and is likely to result in its gas transmission segment annual revenue increasing by ~INR 20bn to around ~INR 80bn at 3QFY23 volume of 104mmcmd, and rising further to +INR 90bn in FY24 assuming gas transmission volume jumps to 120mmcmd. The management expects the government to accept the Kirit Parikh (KP) committee ...
Buy Gail India Ltd For Target Rs .125- JM Financial Institutional Securities Ltd
Buy Gail India Ltd For Target Rs .125- JM Financial Institutional Securities Ltd
Source: JM Financial Institutional Securities Ltd
23/03/2023 11:48:33 AM
Buy CEAT Ltd For Target Rs. 1,800 - JM Financial We visited CEAT’s Halol plant, its largest PCR and TBR plant in India. Company’s focus on quality and efficiency improvement through automation, digitization and advanced analytic tools is impressive. This has helped the company reduce costs by over 15% and improve overall plant productivity. R&D investments over the last 3-4 years have started yielding results and the company has strong new product pipeline in PCR and TBR segments for both domestic and exports. CEAT is also l...
Buy CEAT Ltd For Target Rs. 1,800 - JM Financial
Buy CEAT Ltd For Target Rs. 1,800 - JM Financial
Source: JM Financial
22/03/2023 2:47:08 PM
Buy Axis Bank Ltd For Target Rs. 1,120 - JM Financial Institutional Securities Ltd Axis Bank today completed the acquisition of Citibank's consumer businesses in India (announced in Mar2022). The total consideration to be paid has been revised lower than previously announced to INR 116bn (-6% reported earlier) given runoff in deposits (by 21%), lower credit cards (by 3%) and other adjustments. Despite the decline, the overall profitability is likely to be similar to what was previously announced at INR 8-8.5bn on this portfolio. Axis Bank will incur transition and servi...
Buy Axis Bank Ltd For Target Rs. 1,120 - JM Financial Institutional Securities Ltd
Buy Axis Bank Ltd For Target Rs. 1,120 - JM Financial Institutional Securities Ltd
Source: JM Financial Institutional Securities Ltd
22/03/2023 2:40:21 PM
Buy Jindal Steel & Power Ltd For Target Rs 690 - JM Financial Jindal Steel and Power (JSP) has undergone a significant transformation over the past few years, deleveraging its balance sheet through divestment of non-core operations. The company has embarked on an ambitious capacity expansion to emerge as a flats (steel products) heavy player. The Angul capex program is a low-hanging fruit offering low-cost, short-gestation and value-accretive brownfield expansion which will increase JSP’s crude steel capacity from 9.6 mtpa in FY22 to 15.9 mtpa by ...
Buy Jindal Steel & Power Ltd For Target Rs 690 - JM Financial
Buy Jindal Steel & Power Ltd For Target Rs 690 - JM Financial
Source: JM Financial
22/03/2023 12:45:16 PM
Buy Dr Lal Pathlabs Ltd For Target Rs. 2,620 - JM Financial Institutional Securities Suburban execution key to West expansion We visited Suburban’s new state-of-the-art Vidyavihar lab which will strengthen DLPL’s presence in the West. It enhances test offering while reducing dependency on Delhi National Reference Laboratory (‘NLR’). Pre-acquisition, Suburban outsourced many specialised tests to others which have now been shifted in-house. This lab mirrors 90% testing capability vs. DLPL’s Delhi NLR despite operating in just ~15% of the area. T...
Buy Dr Lal Pathlabs Ltd For Target Rs. 2,620 - JM Financial Institutional Securities
Buy Dr Lal Pathlabs Ltd For Target Rs. 2,620 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities Ltd
21/03/2023 10:56:18 AM
Dr. Lal PathLabs jumps on selecting Kyndryl to manage IT infrastructure stack Dr. Lal Pathlabs is currently trading at Rs. 1851.40, up by 16.15 points or 0.88% from its previous closing of Rs. 1835.25 on the BSE. The scrip opened at Rs. 1849.95 and has touched a high and low of Rs. 1871.70 and Rs. 1835.15 respectively. So far 9255 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 2870.00 on 28-Apr-2022 and a 52 week low of Rs. 1781.15 on 14-Mar-2023. Last one week high and low of the scrip...
Dr. Lal PathLabs jumps on selecting Kyndryl to manage IT infrastructure stack
Dr. Lal PathLabs jumps on selecting Kyndryl to manage IT infrastructure stack
Source: Accord Fintech
15/03/2023 3:38:12 PM
Reduce Dr Lal Pathlabs Ltd For Target Rs. 1,800 - Yes Securities Weak volume outlook Result Synopsis Dr Lal reported a weak revenue quarter as growth declined 1.5% YoY and on a like to like basis excluding Suburban (since it was consolidated for only 45 days in Q3 FY22), reckon decline is more like ~5% YoY. Patient volume declined ~5% YoY and again due lack of full Suburban benefit in base quarter, core DLPL volume would have had a larger fall YoY. Margin came in at 23% on better cost control as also transaction related costs in the base quarter D...
Reduce Dr Lal Pathlabs Ltd For Target Rs. 1,800 - Yes Securities
Reduce Dr Lal Pathlabs Ltd For Target Rs. 1,800 - Yes Securities
Source: Yes Securities Ltd
14/03/2023 10:47:33 AM
Key News - Dr Lal PathLabs Ltd ,Titan Ltd , Kalpataru Power Transmission Ltd, APL Apollo Ltd By ARETE Securities Key News Dr Lal PathLabs Q3 net down 7% to Rs 54 cr, revenue declines to Rs 489 cr: Dr Lal PathLabs on Thursday said its consolidated profit after tax declined 7 per cent to Rs 54 crore for the December quarter. The company had reported a net profit of Rs 58 crore in the October-December quarter of the previous fiscal. Revenue also declined to Rs 489 crore for the period under review as compared with Rs 497 crore in the year-ago period, the company said in a regulatory filing. Titan ...
Key News - Dr Lal PathLabs Ltd ,Titan Ltd , Kalpataru Power Transmission Ltd, APL Apollo Ltd By ARETE Securities
Key News - Dr Lal PathLabs Ltd ,Titan Ltd , Kalpataru Power Transmission Ltd, APL Apollo Ltd By ARETE Securities
Source: ARETE Securities Ltd
3/02/2023 9:32:59 AM
Dr. Lal Pathlabs moves up as its arm gets nod to acquire further 10% stake in APRL PathLabs Dr. Lal Pathlabs is currently trading at Rs. 2077.40, up by 17.35 points or 0.84% from its previous closing of Rs. 2060.05 on the BSE. The scrip opened at Rs. 2089.95 and has touched a high and low of Rs. 2089.95 and Rs. 2038.95 respectively. So far 778 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 3270.30 on 02-Feb-2022 and a 52 week low of Rs. 1805.10 on 26-May-2022. Last one week high and low of the scrip ...
Dr. Lal Pathlabs moves up as its arm gets nod to acquire further 10% stake in APRL PathLabs
Dr. Lal Pathlabs moves up as its arm gets nod to acquire further 10% stake in APRL PathLabs
Source: Accord Fintech
31/01/2023 10:30:38 AM
Healthcare stocks jump amid recent spike in cases of COVID-19 in some countries Shares of the healthcare service providers are trading higher, as Union Minister of Health and Family Welfare Mansukh Mandaviya chaired a high-level meeting to review the COVID-19 situation in India and preparedness of public health system for surveillance, containment and management of COVID-19 in view of the recent spike in cases of COVID-19 in some countries. Metropolis Healthcare is currently trading at Rs. 1370.80, up by 89.10 points or 6.95% from its previous closing of Rs. 1281.70 o...
Healthcare stocks jump amid recent spike in cases of COVID-19 in some countries
Healthcare stocks jump amid recent spike in cases of COVID-19 in some countries
Source: Accord Fintech
21/12/2022 3:50:25 PM
Add Dr Lal Pathlabs Ltd For Target Rs.2,911 - ICICI Securities Margins improve despite slow growth Dr Lal Pathlabs’ (Dr Lal) Q2FY23 performance was a mixed bag with slower-than- expected growth in non-covid patient volumes, but healthy improvement in margins. Base business revenue (ex-Suburban) grew 6.5% YoY on a high base (3-year CAGR of 9%) to Rs4.8bn. Overall revenue was up 7.1% YoY at Rs5.3bn (I-Sec: Rs5.8bn). EBITDA margin contracted 150bps YoY, but grew 360bps QoQ to 26.9%. Adjusted PAT declined 24.5% YoY to Rs717mn. While intensified comp...
Add Dr Lal Pathlabs Ltd For Target Rs.2,911 - ICICI Securities
Add Dr Lal Pathlabs Ltd For Target Rs.2,911 - ICICI Securities
Source: ICICI Securities
24/11/2022 2:09:20 PM
Buy Dr.Lal Path labs Ltd For Target Rs.2900 - JM Financial Institutional Securities Margin surprise highlights core strength Dr Lal PathLabs (‘DLPL’) reported 15%YoY growth in Non-Covid revenues with margins expanding to 26.9% (adjusted 28%) aided by seasonality and improving realisation. Average realisation per patient (‘ARPP’) improved to INR 746 (vs. INR 729 QoQ) as Swasthfit contribution increased to 20% (INR 950mn), a new trend emerging post pandemic supported by marketing focus. Patient volumes (ex-Covid) grew 11%YoY to 7mn. Growth (exSuburba...
Buy Dr.Lal Path labs Ltd For Target Rs.2900 - JM Financial Institutional Securities
Buy Dr.Lal Path labs Ltd For Target Rs.2900 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities Ltd
14/11/2022 10:26:24 AM
Sell Dr.Lal Path labs Ltd For Target Rs.2150 - Centrum Broking In?line quarter; near?term pressure remain   DLPL reported Q2FY23 results in?line with our expectation, with overall sales grew by 7% YoY and 6% QoQ to Rs5.4bn (Ex Covid sales grew by 14.8% YoY). Gross margins for the quarter stood stable at 78.2%. Lower employee cost and b...
Sell Dr.Lal Path labs Ltd For Target Rs.2150 - Centrum Broking
Sell Dr.Lal Path labs Ltd For Target Rs.2150 - Centrum Broking
Source: Centrum Broking
10/11/2022 12:18:47 PM
India`s Dr. Lal PathLabs Q2 profit slumps on falling COVID income, higher expenses Indian medical diagnostics firm Dr. Lal PathLabs Ltd on Tuesday reported a 24.5% drop in September quarter profit as a sustained decline in revenue and volume from its COVID-19 related business and higher expenses weighed on margins. Consolidated profit for the quarter ended Sept. 30 came in at 717 million rupees ($8.76 million), compared with 950 million rupees a year ago, the company said in an exchange filing. Falling profits  Analysts on average had expected a profit of ...
India`s Dr. Lal PathLabs Q2 profit slumps on falling COVID income, higher expenses
India`s Dr. Lal PathLabs Q2 profit slumps on falling COVID income, higher expenses
Source: Reuters
8/11/2022 4:52:39 PM
Dr. Lal Pathlabs Ltd Q1 net profit down 35.44% at Rs 79.60 cr The company reported standalone net profit of Rs 79.60 crore for the quarter ended June 30, 2022 as compared to Rs 123.30 crore in the same period last year, registering a year-on-year decline of 35.44 per cent. Net revenue of the company declined substantially by 22.23 per cent at Rs 439.30 crore in April-June quarter of this fiscal as against Rs 564.90 crore in the corresponding period last year. During April-June quarter, operating expenses dropped by 15.84 per cent to Rs 329.90 crore f...
Dr. Lal Pathlabs Ltd Q1 net profit down 35.44% at Rs 79.60 cr
Dr. Lal Pathlabs Ltd Q1 net profit down 35.44% at Rs 79.60 cr
Source: Dion Global Solutions Ltd
28/07/2022 4:35:24 PM
Dr. Lal Pathlabs tumbles on reporting 27% fall in Q4 consolidated net profit Dr. Lal Pathlabs is currently trading at Rs. 1933.10, down by 120.05 points or 5.85% from its previous closing of Rs. 2053.15 on the BSE. The scrip opened at Rs. 1978.20 and has touched a high and low of Rs. 2000.00 and Rs. 1920.00 respectively. So far 37033 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4243.00 on 15-Sep-2021 and a 52 week low of Rs. 2019.10 on 18-May-2022. Last one week high and low of the s...
Dr. Lal Pathlabs tumbles on reporting 27% fall in Q4 consolidated net profit
Dr. Lal Pathlabs tumbles on reporting 27% fall in Q4 consolidated net profit
Source: Accord Fintech
19/05/2022 3:11:19 PM
Add Dr Lal Pathlabs Ltd For Target Rs.2900 - Yes Securities Margin woes may not be structural Result Synopsis Dr Lal 4Q revenues were up 13%, slightly higher than our estimates. This was the first quarter having full impact of Suburban acquisition. Also, company saw some impact on non-covid revenues in the month of January due to the impact of Omicron. Company hopes to maintain March month double digit growth but intense competitive intensity to impact overall growth. Margins expected to come back to pre-Covid levels as high operating leverage o...
Add Dr Lal Pathlabs Ltd For Target Rs.2900 - Yes Securities
Add Dr Lal Pathlabs Ltd For Target Rs.2900 - Yes Securities
Source: Yes Securities Ltd
18/05/2022 2:29:40 PM
High Conviction Idea : Buy Dr. Lal Pathlabs Ltd For Target Rs.4,999 - Centrum Broking Business Overview Dr Lal PathLabs (DLPL) is the largest diagnostics player in India. Its dominance in the NCR acts as a base for consistent cash flows and provides expansion support. Patient CAGR over five years has been 11%. DLPL has largely expanded organically; meanwhile, the share of non-North region has grown from 28% in FY16 to 34% to FY21. DLPL’s acquisition spree has been gradual; its expansion with new labs at Mumbai and Bangalore should aid growth and deepen presence in oth...
High Conviction Idea : Buy Dr. Lal Pathlabs Ltd For Target Rs.4,999 - Centrum Broking
High Conviction Idea : Buy Dr. Lal Pathlabs Ltd For Target Rs.4,999 - Centrum Broking
Source: Centrum Broking Ltd
2/03/2022 11:03:35 AM
Key News - Union Bank of India Ltd, MRF Ltd , Hindalco Industries , Bharat Forge, Dr Lal Path Labs By ARETE Securities Key News Union Bank of India looks to move to a new tax regime in FY23 Union Bank of India is looking to move to a new tax regime in the next financial year. It will use Rs 12,000 crore — available in the deferred tax asset (DTA) pool — to set off any tax obligations. The public sector lender plans to raise capital via Rs 1,000 crore in additional tier 1 bonds (AT1 bonds) based on market conditions. Rajkiran Rai G, managing director (MD) & chief executive officer (CEO), ...
Key News - Union Bank of India Ltd, MRF Ltd , Hindalco Industries , Bharat Forge, Dr Lal Path Labs By ARETE Securities
Key News - Union Bank of India Ltd, MRF Ltd , Hindalco Industries , Bharat Forge, Dr Lal Path Labs By ARETE Securities
Source: ARETE Securities Ltd
11/02/2022 9:12:04 AM
Add Dr Lal Pathlabs Ltd For Target Rs.3,850 - Yes Securities Suburban acq. overshadows an inline Q Our view Acquisition of Suburban Diagnostics overshadowed what was an inline quarter with Covid revenues on the wane and expected qoq fall in margin. Suburban clocked FY20 revenues of Rs1.7bn though FY21 sales at Rs3bn was bolstered heavily by Covid. With both the leading listed diagnostic companies being active acquirers, it does seem organic growth appears a challenge in new geographies; albeit, we would be cautious of such acquisitions given the ...
Add Dr Lal Pathlabs Ltd For Target Rs.3,850 - Yes Securities
Add Dr Lal Pathlabs Ltd For Target Rs.3,850 - Yes Securities
Source: Yes Securities Ltd
18/11/2021 12:58:19 PM
Add Dr Lal Pathlabs Ltd For Target Rs.3,850 - Yes Securities Suburban acq. overshadows an inline Q Our view Acquisition of Suburban Diagnostics overshadowed what was an inline quarter with Covid revenues on the wane and expected qoq fall in margin. Suburban clocked FY20 revenues of Rs1.7bn though FY21 sales at Rs3bn was bolstered heavily by Covid. With both the leading listed diagnostic companies being active acquirers, it does seem organic growth appears a challenge in new geographies; albeit, we would be cautious of such acquisitions given the ...
Add Dr Lal Pathlabs Ltd For Target Rs.3,850 - Yes Securities
Add Dr Lal Pathlabs Ltd For Target Rs.3,850 - Yes Securities
Source: Yes Securities Ltd
4/11/2021 10:57:20 AM
Quote on Dr. Lal Path labs acquisition of Suburban Diagnostics for ₹1150 crores By Mr. Yash Gupta, Angel One Ltd Below is quote on Dr. Lal Path labs acquisition of Suburban Diagnostics for ₹1150 crores by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd    Dr. Lal Pathlabs Board of director approves acquisition of Suburban Diagnostics Board of Directors of Dr. Lal Pathlabs Limited approves acquisition of 100% stake in Suburban Diagnostics (India) Private Limited. Suburban Diagnostics is a diagnostic chain having a presence in western India ( Maharasht...
Quote on Dr. Lal Path labs acquisition of Suburban Diagnostics for ₹1150 crores By Mr. Yash Gupta, Angel One Ltd
Quote on Dr. Lal Path labs acquisition of Suburban Diagnostics for ₹1150 crores By Mr. Yash Gupta, Angel One Ltd
Source: Angel One Ltd
28/10/2021 12:25:36 PM
India’s largest diagnostics chain unfazed by disruptors By Dr Om Manchanda, CEO – Dr Lal PathLabs, - Motilal Oswal Below are Views On India’s largest diagnostics chain unfazed by disruptors By Dr Om Manchanda, CEO – Dr Lal PathLabs, - Motilal Oswal Key technological developments to watch out for over the next 5–10 years Directionally, tests are moving from chemistry-driven tests to the molecular level. With molecular-level testing, ailments can be picked up much earlier than through chemistry-based testing. These molecular test results could be used for a more targeted treatme...
India’s largest diagnostics chain unfazed by disruptors By Dr Om Manchanda, CEO – Dr Lal PathLabs, - Motilal Oswal
India’s largest diagnostics chain unfazed by disruptors By Dr Om Manchanda, CEO – Dr Lal PathLabs, - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
13/09/2021 12:24:59 PM
Hold Dr Lal Pathlabs Ltd : COVID driven upside; base business steady - ICICI Securities Hold Dr Lal Pathlabs Ltd For Target Rs.3,405 COVID driven upside; base business steady Dr Lal Pathlabs’ (Dr Lal) Q1FY22 performance was above estimate due to higher revenue from COVID-19 related tests. COVID-19 and allied tests contribution increased to 36.3% of sales (13.2% in Q4FY21). Base business revenues grew 84.1% YoY, two year CAGR of 7.4% to Rs3.8bn vs estimated Rs4.1bn. Overall, revenue grew 128%, EBITDA margin was up 1300bps YoY to 31.2% and adj. PAT was up 362% to Rs1.3...
Hold Dr Lal Pathlabs Ltd : COVID driven upside; base business steady - ICICI Securities
Hold Dr Lal Pathlabs Ltd : COVID driven upside; base business steady - ICICI Securities
Source: ICICI Securities
13/09/2021 11:15:15 AM
Mid Cap : Accumulate Dr. Lal PathLabs Ltd For Target Rs. 4,280 - Geojit Financial Significant rise in COVID testing Dr. Lal PathLabs Limited (DLPL) provides diagnostic and related healthcare tests and services in India and internationally. The company has 231 clinical laboratories, 3,705 patient service centers (PSC) and 9,247 pick-up points (PUP) as of march 2021. * Revenue surged 128.0% YoY to Rs. 607cr (+40.7% QoQ), and was above expectation. Total COVID and COVID-allied contribution was at 36% in Q1FY22 (vs. 23% in Q1FY21). * Patient volumes rose 101.4% YoY ba...
Mid Cap : Accumulate Dr. Lal PathLabs Ltd For Target Rs. 4,280 - Geojit Financial
Mid Cap : Accumulate Dr. Lal PathLabs Ltd For Target Rs. 4,280 - Geojit Financial
Source: Geojit Financial Services
6/08/2021 3:00:03 PM
Dr. Lal Pathlabs zooms on reporting around 5-fold jump in Q1 consolidated net profit Dr. Lal Pathlabs is currently trading at Rs. 4011.10, up by 278.60 points or 7.46% from its previous closing of Rs. 3732.50 on the BSE. The scrip opened at Rs. 3750.00 and has touched a high and low of Rs. 4047.95 and Rs. 3642.00 respectively. So far 58674 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4,047.95 on 30-Jul-2021 and a 52 week low of Rs. 1740.60 on 01-Sep-2020. Last one week high and low of the sc...
Dr. Lal Pathlabs zooms on reporting around 5-fold jump in Q1 consolidated net profit
Dr. Lal Pathlabs zooms on reporting around 5-fold jump in Q1 consolidated net profit
Source: Accord Fintech
30/07/2021 2:14:38 PM
Add Dr Lal Pathlabs Ltd For Target Rs.3,000 - ICICI Securities Industry leading performance continues Dr Lal Pathlabs’ (Dr Lal) Q4FY21 performance was above estimate with strong growth recovery in the ex-COVID business and higher revenue from COVID-19 related tests. Though, COVID-19 and allied tests contribution dropped to 11.2% of sales (21.6% in Q3FY21). Base business revenues grew 28.6% YoY. Overall, revenue grew 42.9%, EBITDA margin was up 930bps YoY to 28.3% and adj. PAT was up 157% to Rs834mn. The base business has seen good recovery Qo...
Add Dr Lal Pathlabs Ltd For Target Rs.3,000 - ICICI Securities
Add Dr Lal Pathlabs Ltd For Target Rs.3,000 - ICICI Securities
Source: ICICI Securities Ltd
1/06/2021 11:48:14 AM
Add Dr Lal Pathlabs Ltd For Target Rs. 3,000 - Yes Securities Result Highlights * 43% jump in Q4 sales on YoY rebound in non COVID business on low base of last year; 33% rise in patient volumes * Impact of second wave not as severe on patient footfalls as last year due to localized lockdowns in Q4 * Aims for expansion in western and Southern markets through regional reference labs; ramp up in new markets would be keenly eyed.     Our view: At Rs15bn revenue, DLPL is amongst largest diagnostic players with a large runway ...
Add Dr Lal Pathlabs Ltd For Target Rs. 3,000 - Yes Securities
Add Dr Lal Pathlabs Ltd For Target Rs. 3,000 - Yes Securities
Source: Yes Securities Ltd
24/05/2021 11:24:08 AM
Buy Dr. Lal Pathlabs Ltd For Target Rs.2,985 - HDFC Securities Our Take:   Dr Lal PathLabs (DLPL) is a leading player in the highly fragmented and competitive Indian diagnostics market and is well-positioned to benefit from favourable sector dynamics. DLPL has a robust hub-and-spoke model, with strategically positioned clinical laboratories, patient service centers (PSCs), and pick-up points (PUPs). The company’s strong business model led to a revenue growth of 15% CAGR over FY15- 20, supported by rise in sample collection (17.1% CAGR; ...
Buy Dr. Lal Pathlabs Ltd For Target Rs.2,985 - HDFC Securities
Buy Dr. Lal Pathlabs Ltd For Target Rs.2,985 - HDFC Securities
Source: HDFC Securities Ltd
30/03/2021 9:52:46 AM
Add Dr Lal Pathlabs Ltd For Target Rs.2,540 - ICICI Securities Maintains superior execution Dr Lal Pathlabs’ (Dr Lal) Q3FY21 performance was above estimate even in a challenging environment, aided by COVID-19 tests as well as speedy recovery in base business. COVID-19 and allied tests contributed 21.6% to sales. Other revenues grew 8.3% YoY. Overall, revenue grew 38.0%, EBITDA margin was up 560/120bps YoY/QoQ to 30.7% and adj. PAT was up 74.7% to Rs945mn. The base business has seen very good recovery and we expect healthy growth in coming quart...
Add Dr Lal Pathlabs Ltd For Target Rs.2,540 - ICICI Securities
Add Dr Lal Pathlabs Ltd For Target Rs.2,540 - ICICI Securities
Source: ICICI Securities Ltd
10/02/2021 12:31:53 PM